Posted on by admin

Progressive Supranuclear Palsy Market Statistics Expected to Experience Major Growth by 2032, According to DelveInsight | Woolsey Pharma, Asahi Kasei Pharma, AlzProtect, Amylyx Pharma, Transposon

The Key Progressive Supranuclear Palsy Companies in the market include – Woolsey Pharmaceutical, Asahi Kasei Pharma, AlzProtect, Amylyx Pharmaceuticals, Transposon Therapeutics, Oncolys Biopharma’s, Ferrer/Asceneuron, GemVax & Kael, Ferrer Internacional S.A., Allon Therapeutics, Amylyx Pharmaceuticals, EmeraMed, and others.

 

DelveInsight’s “Progressive Supranuclear Palsy Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Progressive Supranuclear Palsy, historical and forecasted epidemiology as well as the Progressive Supranuclear Palsy market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

The latest healthcare forecast report provides an in-depth analysis of Progressive Supranuclear Palsy, offering comprehensive insights into the Progressive Supranuclear Palsy revenue trends, prevalence, and treatment landscape. The report delves into key Progressive Supranuclear Palsy statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Progressive Supranuclear Palsy therapies. Additionally, we cover the landscape of Progressive Supranuclear Palsy clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Progressive Supranuclear Palsy treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Progressive Supranuclear Palsy space.

 

To Know in detail about the Progressive Supranuclear Palsy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Progressive Supranuclear Palsy Market Forecast

 

Some of the key facts of the Progressive Supranuclear Palsy Market Report: 

  • The Progressive Supranuclear Palsy market size was valued ~USD 8.3 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2019-2032)

  • In October 2024, GemVax & KAEL Co., Ltd. (“GemVax”; KOSDAQ ticker: 082270) announced that the topline results from the Phase 2a clinical trial (the “Phase 2a PSP Clinical Trial”) of GV1001, an experimental peptide drug for treating progressive supranuclear palsy (“PSP”), were presented at “Neuro2024.”

  • In September 2024, Ferrer, a B Corp-certified global pharmaceutical company, announced the administration of the first dose in the Phase II clinical trial, PROSPER. The trial aims to assess the safety and efficacy of FNP-223,1, a new therapy designed to slow the progression of Progressive Supranuclear Palsy (PSP).

  • In 2022, the US held the largest market share for PSP, accounting for around 44% of the total PSP market. This is expected to grow significantly during the study period with the introduction of new market players.

  • In 2022, the PSP market size in EU4 and the UK was approximately USD 2.4 million. DelveInsight’s analysis indicates that the market is expected to grow during the study period.

  • In 2022, Germany had the largest market size in EU4 and the UK, with approximately USD 0.6 million, while Spain had the smallest. The market is projected to grow, with Germany expected to maintain the largest share, followed by Italy in 2032.

  • Key Progressive Supranuclear Palsy Companies: Woolsey Pharmaceutical, Asahi Kasei Pharma, AlzProtect, Amylyx Pharmaceuticals, Transposon Therapeutics, Oncolys Biopharma’s, Ferrer/Asceneuron, GemVax & Kael, Ferrer Internacional S.A., Allon Therapeutics, Amylyx Pharmaceuticals, EmeraMed, and others

  • Key Progressive Supranuclear Palsy Therapies: BRAVYL (fasudil), AZP2006 (ezeprogind), AMX0035, TPN-101/OBP-601 (censavudine), ASN90, GV1001, FNP-223, Davunetide, AMX0035, NBMI, and others

  • The Progressive Supranuclear Palsy market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Progressive Supranuclear Palsy pipeline products will significantly revolutionize the Progressive Supranuclear Palsy market dynamics.

  • In 2022, the total number of prevalent Progressive Supranuclear Palsy (PSP) cases was estimated to be around 80,706 across the 7MM. 

  • In 2022, Japan had the highest prevalence of Progressive Supranuclear Palsy (PSP), contributing almost 29%, while Spain had the lowest, accounting for about 7% of the total prevalent cases.

  • According to DelveInsight analysis, in 2022, the United States had the highest number of diagnosed prevalent cases, representing approximately 33% of the total cases across the 7MM countries.

  • Among the EU4 and the UK, Germany reported the highest number of diagnosed prevalent cases of PSP, with approximately 1,646 cases, while Spain had the lowest, with around 941 cases in 2022.

  • In 2022, approximately 3,077 males and 2,674 females in the US were diagnosed with PSP.  

 

Progressive Supranuclear Palsy Overview

Progressive supranuclear palsy (PSP) is a rare, degenerative neurological disorder that affects movement, balance, vision, speech, and swallowing. It is caused by the deterioration of cells in the brain, particularly in areas that control these functions, such as the brainstem and basal ganglia. Symptoms of PSP typically include difficulty with balance and walking, eye movement problems (especially looking up or down), stiffness, and slurred speech. PSP progresses over time, and there is currently no cure, though treatment can help manage symptoms. It is often misdiagnosed as Parkinson’s disease due to overlapping symptoms.

 

Get a Free sample for the Progressive Supranuclear Palsy Market Forecast, Size & Share Analysis Report: 

https://www.delveinsight.com/report-store/progressive-supranuclear-palsy-market

 

Progressive Supranuclear Palsy Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Progressive Supranuclear Palsy Epidemiology Segmentation:

The Progressive Supranuclear Palsy market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalent Cases of PSP in the 7MM

  • Total Diagnosed Prevalent Cases of PSP in the 7MM

  • Gender-specific Diagnosed Prevalent Cases of PSP in the 7MM

  • Phenotype-specific Diagnosed Prevalent Cases of PSP in the 7MM

  • Comorbidity Associated Cases with PSP in the 7MM

 

Download the report to understand which factors are driving Progressive Supranuclear Palsy epidemiology trends @ Progressive Supranuclear Palsy Epidemiology Forecast

 

Progressive Supranuclear Palsy Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Progressive Supranuclear Palsy market or expected to get launched during the study period. The analysis covers Progressive Supranuclear Palsy market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Progressive Supranuclear Palsy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Progressive Supranuclear Palsy Therapies and Key Companies

  • BRAVYL (fasudil): Woolsey Pharmaceutical/Asahi Kasei Pharma

  • AZP2006 (ezeprogind): AlzProtect

  • AMX0035: Amylyx Pharmaceuticals

  • TPN-101/OBP-601 (censavudine): Transposon Therapeutics/Oncolys Biopharma’s

  • ASN90: Ferrer/Asceneuron

  • GV1001: GemVax & Kael

  • FNP-223: Ferrer Internacional S.A.

  • Davunetide: Allon Therapeutics

  • AMX0035: Amylyx Pharmaceuticals

  • NBMI: EmeraMed

 

Discover more about therapies set to grab major Progressive Supranuclear Palsy market share @ Progressive Supranuclear Palsy Treatment Landscape

 

Progressive Supranuclear Palsy Market Strengths

  • The new MDS diagnostic criteria for PSP expands the clinical spectrum of the disease by incorporating conditions suggestive of PSP and a variety of symptomatic PSP phenotypes.  

  • Advocacy and support organizations are dedicated to raising awareness, providing resources, and supporting PSP-affected individuals and families.

  • Improvement in understanding PSP pathogenesis has led to the discovery of potential therapies that target tau protein through various modes of actions

 

Progressive Supranuclear Palsy Market Opportunities

  • The lack of approved therapies provides lucrative opportunities for pharma players to develop disease-modifying therapies and capitalize on the untapped market

  • Increasing research can lead to a deeper understanding of PSP, including its underlying mechanisms, risk factors, and potential therapeutic targets

  • Research focusing on the identification of better imaging and biofluid biomarkers will promote early and accurate diagnosis enrollment of appropriate patients who are likely to show more clear beneficial effects in clinical trials

 

Scope of the Progressive Supranuclear Palsy Market Report

  • Study Period: 2019–2032

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Progressive Supranuclear Palsy Companies: Woolsey Pharmaceutical, Asahi Kasei Pharma, AlzProtect, Amylyx Pharmaceuticals, Transposon Therapeutics, Oncolys Biopharma’s, Ferrer/Asceneuron, GemVax & Kael, Ferrer Internacional S.A., Allon Therapeutics, Amylyx Pharmaceuticals, EmeraMed, and others

  • Key Progressive Supranuclear Palsy Therapies: BRAVYL (fasudil), AZP2006 (ezeprogind), AMX0035, TPN-101/OBP-601 (censavudine), ASN90, GV1001, FNP-223, Davunetide, AMX0035, NBMI, and others

  • Progressive Supranuclear Palsy Therapeutic Assessment: Progressive Supranuclear Palsy current marketed and Progressive Supranuclear Palsy emerging therapies

  • Progressive Supranuclear Palsy Market Dynamics: Progressive Supranuclear Palsy market drivers and Progressive Supranuclear Palsy market barriers 

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Progressive Supranuclear Palsy Unmet Needs, KOL’s views, Analyst’s views, Progressive Supranuclear Palsy Market Access and Reimbursement 

 

To know more about Progressive Supranuclear Palsy companies working in the treatment market, visit @ Progressive Supranuclear Palsy Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Progressive Supranuclear Palsy Market Report Introduction

2. Executive Summary for Progressive Supranuclear Palsy

3. SWOT analysis of Progressive Supranuclear Palsy

4. Progressive Supranuclear Palsy Patient Share (%) Overview at a Glance

5. Progressive Supranuclear Palsy Market Overview at a Glance

6. Progressive Supranuclear Palsy Disease Background and Overview

7. Progressive Supranuclear Palsy Epidemiology and Patient Population

8. Country-Specific Patient Population of Progressive Supranuclear Palsy 

9. Progressive Supranuclear Palsy Current Treatment and Medical Practices

10. Progressive Supranuclear Palsy Unmet Needs

11. Progressive Supranuclear Palsy Emerging Therapies

12. Progressive Supranuclear Palsy Market Outlook

13. Country-Wise Progressive Supranuclear Palsy Market Analysis (2019–2032)

14. Progressive Supranuclear Palsy Market Access and Reimbursement of Therapies

15. Progressive Supranuclear Palsy Market Drivers

16. Progressive Supranuclear Palsy Market Barriers

17.  Progressive Supranuclear Palsy Appendix

18. Progressive Supranuclear Palsy Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/